← Leaderboards
Komaraiah Palle
Texas Tech University Health Scis Center
$3,685,877
Attributed
$3,685,877
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $698.7K · FY2012–23$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,685,877 · 2
By mechanism
R01$3,685,877 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProteinsResponseMediatingPathway InteractionsPharmaceutical PreparationsDna RepairMolecularCellsDna DamageRepairedRegulationMutantDna Repair PathwayDna BiosynthesisTumorBaseGenome StabilityDna LesionNovel TherapeuticsComb Animal StructureCancer CellInhibitor/AntagonistDesign
Grant awards (13)
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence$317,162
R01 · FY2023 · CA · contact PI
Hedgehog/GLI1-mediated regulation of DNA repair in cancer, aging and neurodegenerative diseases$382,500
R01 · FY2022 · CA · contact PI
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence$316,179
R01 · FY2022 · CA · contact PI
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence$53,709
R01 · FY2021 · CA · contact PI
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence$563,747
R01 · FY2020 · CA · contact PI
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence$566,496
R01 · FY2019 · CA · contact PI
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence$350,750
R01 · FY2018 · CA · contact PI
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin$228,690
R01 · FY2016 · GM · contact PI
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin$228,690
R01 · FY2015 · GM · contact PI
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin$228,690
R01 · FY2014 · GM · contact PI
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin$220,686
R01 · FY2013 · GM · contact PI
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin$195,500
R01 · FY2012 · GM · contact PI
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin$33,078
R01 · FY2012 · GM · contact PI